Close Menu

NEW YORK – On Tuesday, Turning Point Therapeutics and Zai Lab said that they entered into an exclusive license agreement for the development and commercialization of repotrectinib in China, Hong Kong, Macau and Taiwan.

The agreement will give Zai Lab exclusive rights to develop and commercialize repotrectinib in those territories. Turning Point Therapeutics will receive a $25 million upfront payment, up to $151 million in developmental and regulatory, and sales-based milestone payments, as well as royalties based on sales of repotrectinib.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.